Get the Stockscreener App
24.13
3.60%
1.09
Dbv Technologies Adr stock is traded at $24.13, with a volume of 772.82K.
It is up +3.60% in the last 24 hours and up +26.16% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
See More
Previous Close:
$23.04
Open:
$24.7
24h Volume:
772.82K
Relative Volume:
1.86
Market Cap:
$1.31B
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-22.98
EPS:
-1.05
Net Cash Flow:
$-108.72M
1W Performance:
+14.87%
1M Performance:
+26.16%
6M Performance:
+152.10%
1Y Performance:
+442.50%
1-Day Range:
$23.75
$25.40
1-Week Range:
$20.52
$25.40
52-Week Range:
$3.8001
$26.18
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
24.13 | 1.25B | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Guggenheim | Buy |
| May-29-25 | Resumed | Goldman | Sell |
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Still a Buy? - Defense World
DBV Technologies Announces €166.7 Million in Gross Proceeds - GlobeNewswire
DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d'euros suite à l'exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025 - GlobeNewswire Inc.
European ADRs Slipped, But Biotech Names Still Stole The Show - Finimize
Worthington Steel, Immunitybio, Riot Platforms, Micron Technology And Other Big Stocks Moving Higher On Friday - Benzinga
DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - The Manila Times
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - MSN
The Insider Report: A Tape Fitting for the Holiday - Sahm
European ADRs Started The Week Higher, Led By Biotech - Finimize
Sidus Space, Starfighters Space And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Honeywell, Intuitive Machines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
DBV Technologies (NASDAQ:DBVT) Shares Gap Down on Insider Selling - Defense World
H.C Wainwright and Citizens Raise PT on DBV Technologies (DBVT) Following Phase 3 VITESSE Trial Result - Finviz
Stock Market Today 21.12.2025 - ts2.tech
HC Wainwright Boosts Earnings Estimates for DBV Technologies - Defense World
DBV Technologies (NASDAQ:DBVT) Given New $45.00 Price Target at Citizens Jmp - Defense World
DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
HC Wainwright Has Positive Outlook for DBVT FY2026 Earnings - Defense World
European Stocks On Wall Street Delivered Modest Moves For Investors - Finimize
Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
DBV Technologies (NASDAQ:DBVT) Sets New 12-Month High on Analyst Upgrade - Defense World
Crude Oil Rises Over 1%; General Mills Earnings Top Views - Benzinga
Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday - Benzinga
Citizens raises DBV Technologies stock price target to $45 on Viaskin Peanut success By Investing.com - ca.investing.com
Pre Market Movers: DBVT, YCBD, KYTX Set The Pace - RTTNews
Citizens raises DBV Technologies stock price target to $45 on Viaskin Peanut success - Investing.com UK
DBV Technologies receive positive results in key study with peanut patch - medwatch.com
Why Aditxt Shares Are Trading Higher By Around 63%; Here Are 20 Stocks Moving Premarket - Benzinga
DBV Technologies (NASDAQ:DBVT) Builds Long-Term Clinical Direction - Kalkine Media
Cantor Fitzgerald Upgrades DBV Technologies (NASDAQ:DBVT) to “Strong-Buy” - Defense World
DBV Technologies stock soars after positive Phase 3 trial results - Investing.com
DBV Technologies Reports Positive Phase 3 Trial Results - TipRanks
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years - The Manila Times
DBV Technologies Announces Positive Topline Results from - GlobeNewswire
Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing - Sahm
DBV Technologies (NASDAQ:DBVT) Shares Gap DownTime to Sell? - MarketBeat
Micron Technology To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
This SiTime Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
DBV Technologies stock price target raised to $35 from $20 at H.C. Wainwright - Investing.com
DBV Technologies stock initiated with Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
DBV Technologies stock initiated with Overweight rating at Cantor Fitzgerald - Investing.com
European Companies Trading In The US Notched Gains This Week - Finimize
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dbv Technologies Adr Stock (DBVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EPIC Bpifrance | Member of 10% owner group |
Dec 18 '25 |
Sale |
4.19 |
1,292,103 |
5,413,912 |
7,303,369 |
| Mohideen Pharis | Chief Medical Officer |
Nov 20 '25 |
Sale |
2.88 |
6,496 |
18,708 |
103,153 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '25 |
Sale |
2.77 |
1,624 |
4,498 |
101,529 |
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '25 |
Sale |
2.22 |
464 |
1,030 |
109,649 |
| Mohideen Pharis | Chief Medical Officer |
May 22 '25 |
Sale |
1.84 |
397 |
730 |
110,113 |
| Mohideen Pharis | Chief Medical Officer |
Jan 30 '25 |
Sale |
0.85 |
600 |
510 |
110,510 |
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):